These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 10914239

  • 21. Heparin-induced thrombocytopenia in hemodialysis patients.
    Brouwer DJ, Peterson P.
    Nephrol Nurs J; 2000 Apr; 27(2):240-1, 213. PubMed ID: 11111553
    [No Abstract] [Full Text] [Related]

  • 22. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s.
    Lubenow N, Warkentin TE, Greinacher A, Wessel A, Sloane DA, Krahn EL, Magnani HN.
    Thromb Res; 2006 Apr; 117(5):507-15. PubMed ID: 15907979
    [Abstract] [Full Text] [Related]

  • 23. Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy.
    Gill J, Kovacs MJ.
    Obstet Gynecol; 1997 Oct; 90(4 Pt 2):648-50. PubMed ID: 11770579
    [Abstract] [Full Text] [Related]

  • 24. Failure of danaparoid anticoagulation for cardiopulmonary bypass.
    Ariano RE, Bhattacharya SK, Moon M, Brownell LG.
    J Thorac Cardiovasc Surg; 2000 Jan; 119(1):167-8. PubMed ID: 10612777
    [No Abstract] [Full Text] [Related]

  • 25. [Danaparoid (orgaran) for continuous venovenous hemodiafiltration in a patient with heparin-induced thrombocytopenia].
    Christin F, Theissen-Laval O, Loeb JP.
    Ann Fr Anesth Reanim; 1998 Jan; 17(1):82-3. PubMed ID: 9750692
    [No Abstract] [Full Text] [Related]

  • 26. Anticoagulative management of patients requiring left ventricular assist device implantation and suffering from heparin-induced thrombocytopenia type II.
    Christiansen S, Jahn UR, Meyer J, Scheld HH, Van Aken H, Kehrel BE, Hammel D.
    Ann Thorac Surg; 2000 Mar; 69(3):774-7. PubMed ID: 10750760
    [Abstract] [Full Text] [Related]

  • 27. [Extracorporeal circulation with danaparoid sodium for valve replacement in thrombocytopenia induced by type II heparin].
    Salmi L, Leroy-Matheron C, LeBesnerais P, Rosanval O, Duvaldestin P, Gouault-Heilmann M.
    Ann Fr Anesth Reanim; 2001 Nov; 20(9):799-802. PubMed ID: 11759322
    [Abstract] [Full Text] [Related]

  • 28. Heparin-induced thrombocytopenia (HIT): in vitro and in vivo cross-reactivity to danaparoid sodium and successful treatment with recombinant hirudin (lepirudin).
    Baumgärtel MW, Eichler P, Glöckner WM, Ranze O, Greinacher A.
    Eur J Haematol; 2000 Aug; 65(2):148-9. PubMed ID: 10966178
    [No Abstract] [Full Text] [Related]

  • 29. Heparin versus danaparoid in off-pump coronary bypass grafting: results of a prospective randomized clinical trial.
    Carrier M, Robitaille D, Perrault LP, Pellerin M, Pagé P, Cartier R, Bouchard D.
    J Thorac Cardiovasc Surg; 2003 Feb; 125(2):325-9. PubMed ID: 12579101
    [Abstract] [Full Text] [Related]

  • 30. Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium.
    Ranze O, Ranze P, Magnani HN, Greinacher A.
    Eur J Pediatr; 1999 Dec; 158 Suppl 3():S130-3. PubMed ID: 10650852
    [Abstract] [Full Text] [Related]

  • 31. [Value of orgaran in hemodialysis during heparin-induced thrombopenia].
    Lamriben L, Tiberghien F, Delacour JL, Floriot C, Wagschal G, Daoudal P, Ory JP.
    Presse Med; 1996 Sep 28; 25(28):1303. PubMed ID: 8949796
    [No Abstract] [Full Text] [Related]

  • 32. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia.
    Schenk JF, Pindur G, Stephan B, Mörsdorf S, Mertzlufft F, Kroll H, Wenzel E, Seyfert UT.
    Clin Appl Thromb Hemost; 2003 Jan 28; 9(1):25-32. PubMed ID: 12643320
    [Abstract] [Full Text] [Related]

  • 33. Danaparoid sodium (Orgaran) in four children with heparin-induced thrombocytopenia type II.
    Zöhrer' B, Zenz W, Rettenbacher A, Covi P, Kurnik K, Kroll H, Grubbauer HM, Muntean W.
    Acta Paediatr; 2001 Jul 28; 90(7):765-71. PubMed ID: 11519979
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Danaparoid use for haemodialysis in a morbidly obese patient with heparin-induced thrombocytopenia - Need for a higher than recommended weight-based dosing.
    Castelino RL, Maddula M, Tarafdar S, Sud K, Kairaitis L.
    Thromb Res; 2019 Aug 28; 180():70-73. PubMed ID: 31229923
    [Abstract] [Full Text] [Related]

  • 40. Repeated premature hemofilter clotting during regional citrate anticoagulation as indicator of heparin induced thrombocytopenia.
    Lehner GF, Schöpf M, Harler U, Pechlaner C, Joannidis M.
    Blood Purif; 2014 Aug 28; 38(2):127-30. PubMed ID: 25412655
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.